List of Tables
Table 1. Postmenopausal Vaginal Atrophy Drugs Market Trends
Table 2. Postmenopausal Vaginal Atrophy Drugs Market Drivers & Opportunity
Table 3. Postmenopausal Vaginal Atrophy Drugs Market Challenges
Table 4. Postmenopausal Vaginal Atrophy Drugs Market Restraints
Table 5. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Company (2019-2024)
Table 7. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Company (2019-2024) & (K Units)
Table 8. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume Market Share by Company (2019-2024)
Table 9. Global Market Postmenopausal Vaginal Atrophy Drugs Price by Company (2019-2024) & (US$/Unit)
Table 10. Key Manufacturers Postmenopausal Vaginal Atrophy Drugs Manufacturing Base Distribution and Headquarters
Table 11. Key Manufacturers Postmenopausal Vaginal Atrophy Drugs Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Postmenopausal Vaginal Atrophy Drugs
Table 13. Global Postmenopausal Vaginal Atrophy Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Postmenopausal Vaginal Atrophy Drugs as of 2023)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 17. Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (2019-2024) & (US$ Million)
Table 18. Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (2025-2030) & (US$ Million)
Table 19. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Type (2019-2024) & (%)
Table 20. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Type (2025-2030) & (%)
Table 21. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
Table 22. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Type (2019-2024) & (K Units)
Table 23. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Type (2025-2030) & (K Units)
Table 24. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Type (2019-2024) & (%)
Table 25. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Type (2025-2030) & (%)
Table 26. Global Postmenopausal Vaginal Atrophy Drugs Price by Type (2019-2024) & (US$/Unit)
Table 27. Global Postmenopausal Vaginal Atrophy Drugs Price by Type (2025-2030) & (US$/Unit)
Table 28. Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Application (2019-2024) & (US$ Million)
Table 30. Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Application (2025-2030) & (US$ Million)
Table 31. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Application (2019-2024) & (%)
Table 32. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Application (2025-2030) & (%)
Table 33. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
Table 34. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Application (2019-2024) & (K Units)
Table 35. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Application (2025-2030) & (K Units)
Table 36. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Application (2019-2024) & (%)
Table 37. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Application (2025-2030) & (%)
Table 38. Global Postmenopausal Vaginal Atrophy Drugs Price by Application (2019-2024) & (US$/Unit)
Table 39. Global Postmenopausal Vaginal Atrophy Drugs Price by Application (2025-2030) & (US$/Unit)
Table 40. Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Region (2019-2024) & (US$ Million)
Table 42. Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Region (2025-2030) & (US$ Million)
Table 43. Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Region (2019-2024) & (%)
Table 44. Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Region (2025-2030) & (%)
Table 45. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
Table 46. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Region (2019-2024) & (K Units)
Table 47. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Region (2025-2030) & (K Units)
Table 48. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Region (2019-2024) & (%)
Table 49. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Region (2025-2030) & (%)
Table 50. Global Postmenopausal Vaginal Atrophy Drugs Average Price by Region (2019-2024) & (US$/Unit)
Table 51. Global Postmenopausal Vaginal Atrophy Drugs Average Price by Region (2025-2030) & (US$/Unit)
Table 52. Key Countries/Regions Postmenopausal Vaginal Atrophy Drugs Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 53. Key Countries/Regions Postmenopausal Vaginal Atrophy Drugs Sales Value, (2019-2024) & (US$ Million)
Table 54. Key Countries/Regions Postmenopausal Vaginal Atrophy Drugs Sales Value, (2025-2030) & (US$ Million)
Table 55. Key Countries/Regions Postmenopausal Vaginal Atrophy Drugs Sales Volume, (2019-2024) & (K Units)
Table 56. Key Countries/Regions Postmenopausal Vaginal Atrophy Drugs Sales Volume, (2025-2030) & (K Units)
Table 57. Pfizer Inc Company Information
Table 58. Pfizer Inc Introduction and Business Overview
Table 59. Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 60. Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 61. Pfizer Inc Recent Development
Table 62. Mylan NV Company Information
Table 63. Mylan NV Introduction and Business Overview
Table 64. Mylan NV Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 65. Mylan NV Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 66. Mylan NV Recent Development
Table 67. Novartis AG Company Information
Table 68. Novartis AG Introduction and Business Overview
Table 69. Novartis AG Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 70. Novartis AG Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 71. Novartis AG Recent Development
Table 72. Hikma Pharmaceuticals plc Company Information
Table 73. Hikma Pharmaceuticals plc Introduction and Business Overview
Table 74. Hikma Pharmaceuticals plc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 75. Hikma Pharmaceuticals plc Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 76. Hikma Pharmaceuticals plc Recent Development
Table 77. Aurobindo Pharma Company Information
Table 78. Aurobindo Pharma Introduction and Business Overview
Table 79. Aurobindo Pharma Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 80. Aurobindo Pharma Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 81. Aurobindo Pharma Recent Development
Table 82. AbbVie Inc Company Information
Table 83. AbbVie Inc Introduction and Business Overview
Table 84. AbbVie Inc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 85. AbbVie Inc Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 86. AbbVie Inc Recent Development
Table 87. Melinta Therapeutics, Inc Company Information
Table 88. Melinta Therapeutics, Inc Introduction and Business Overview
Table 89. Melinta Therapeutics, Inc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 90. Melinta Therapeutics, Inc Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 91. Melinta Therapeutics, Inc Recent Development
Table 92. Bristol-Myers Squibb Company Company Information
Table 93. Bristol-Myers Squibb Company Introduction and Business Overview
Table 94. Bristol-Myers Squibb Company Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 95. Bristol-Myers Squibb Company Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 96. Bristol-Myers Squibb Company Recent Development
Table 97. GSK plc Company Information
Table 98. GSK plc Introduction and Business Overview
Table 99. GSK plc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 100. GSK plc Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 101. GSK plc Recent Development
Table 102. Bayer AG Company Information
Table 103. Bayer AG Introduction and Business Overview
Table 104. Bayer AG Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 105. Bayer AG Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 106. Bayer AG Recent Development
Table 107. Lupin Company Information
Table 108. Lupin Introduction and Business Overview
Table 109. Lupin Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 110. Lupin Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 111. Lupin Recent Development
Table 112. Perrigo Company plc Company Information
Table 113. Perrigo Company plc Introduction and Business Overview
Table 114. Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 115. Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 116. Perrigo Company plc Recent Development
Table 117. Bionovo, Inc Company Information
Table 118. Bionovo, Inc Introduction and Business Overview
Table 119. Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 120. Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 121. Bionovo, Inc Recent Development
Table 122. TherapeuticsMD, Inc Company Information
Table 123. TherapeuticsMD, Inc Introduction and Business Overview
Table 124. TherapeuticsMD, Inc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 125. TherapeuticsMD, Inc Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 126. TherapeuticsMD, Inc Recent Development
Table 127. Endoceutics, Inc Company Information
Table 128. Endoceutics, Inc Introduction and Business Overview
Table 129. Endoceutics, Inc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 130. Endoceutics, Inc Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 131. Endoceutics, Inc Recent Development
Table 132. Key Raw Materials Lists
Table 133. Raw Materials Key Suppliers Lists
Table 134. Postmenopausal Vaginal Atrophy Drugs Downstream Customers
Table 135. Postmenopausal Vaginal Atrophy Drugs Distributors List
Table 136. Research Programs/Design for This Report
Table 137. Key Data Information from Secondary Sources
Table 138. Key Data Information from Primary Sources
List of Figures
Figure 1. Postmenopausal Vaginal Atrophy Drugs Product Picture
Figure 2. Global Postmenopausal Vaginal Atrophy Drugs Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Postmenopausal Vaginal Atrophy Drugs Sales Value (2019-2030) & (US$ Million)
Figure 4. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume (2019-2030) & (K Units)
Figure 5. Global Postmenopausal Vaginal Atrophy Drugs Sales Price (2019-2030) & (US$/Unit)
Figure 6. Postmenopausal Vaginal Atrophy Drugs Report Years Considered
Figure 7. Global Postmenopausal Vaginal Atrophy Drugs Players Revenue Ranking (2023) & (US$ Million)
Figure 8. Global Postmenopausal Vaginal Atrophy Drugs Players Sales Volume Ranking (2023) & (K Units)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Postmenopausal Vaginal Atrophy Drugs Revenue in 2023
Figure 10. Postmenopausal Vaginal Atrophy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 11. Topical Estrogen Picture
Figure 12. Oral Estrogen Picture
Figure 13. Other Picture
Figure 14. Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 15. Global Postmenopausal Vaginal Atrophy Drugs Sales Value Market Share by Type, 2023 & 2030
Figure 16. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
Figure 17. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume Market Share by Type, 2023 & 2030
Figure 18. Global Postmenopausal Vaginal Atrophy Drugs Price by Type (2019-2030) & (US$/Unit)
Figure 19. Product Picture of Online Pharmacy
Figure 20. Product Picture of Hospital Pharmacy
Figure 21. Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 22. Global Postmenopausal Vaginal Atrophy Drugs Sales Value Market Share by Application, 2023 & 2030
Figure 23. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
Figure 24. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume Market Share by Application, 2023 & 2030
Figure 25. Global Postmenopausal Vaginal Atrophy Drugs Price by Application (2019-2030) & (US$/Unit)
Figure 26. North America Postmenopausal Vaginal Atrophy Drugs Sales Value (2019-2030) & (US$ Million)
Figure 27. North America Postmenopausal Vaginal Atrophy Drugs Sales Value by Country (%), 2023 VS 2030
Figure 28. Europe Postmenopausal Vaginal Atrophy Drugs Sales Value (2019-2030) & (US$ Million)
Figure 29. Europe Postmenopausal Vaginal Atrophy Drugs Sales Value by Country (%), 2023 VS 2030
Figure 30. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Value (2019-2030) & (US$ Million)
Figure 31. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Value by Country (%), 2023 VS 2030
Figure 32. South America Postmenopausal Vaginal Atrophy Drugs Sales Value (2019-2030) & (US$ Million)
Figure 33. South America Postmenopausal Vaginal Atrophy Drugs Sales Value by Country (%), 2023 VS 2030
Figure 34. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Value (2019-2030) & (US$ Million)
Figure 35. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Value by Country (%), 2023 VS 2030
Figure 36. Key Countries/Regions Postmenopausal Vaginal Atrophy Drugs Sales Value (%), (2019-2030)
Figure 37. Key Countries/Regions Postmenopausal Vaginal Atrophy Drugs Sales Volume (%), (2019-2030)
Figure 38. United States Postmenopausal Vaginal Atrophy Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 39. United States Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (%), 2023 VS 2030
Figure 40. United States Postmenopausal Vaginal Atrophy Drugs Sales Value by Application (%), 2023 VS 2030
Figure 41. Europe Postmenopausal Vaginal Atrophy Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 42. Europe Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (%), 2023 VS 2030
Figure 43. Europe Postmenopausal Vaginal Atrophy Drugs Sales Value by Application (%), 2023 VS 2030
Figure 44. China Postmenopausal Vaginal Atrophy Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 45. China Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (%), 2023 VS 2030
Figure 46. China Postmenopausal Vaginal Atrophy Drugs Sales Value by Application (%), 2023 VS 2030
Figure 47. Japan Postmenopausal Vaginal Atrophy Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 48. Japan Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (%), 2023 VS 2030
Figure 49. Japan Postmenopausal Vaginal Atrophy Drugs Sales Value by Application (%), 2023 VS 2030
Figure 50. South Korea Postmenopausal Vaginal Atrophy Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 51. South Korea Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (%), 2023 VS 2030
Figure 52. South Korea Postmenopausal Vaginal Atrophy Drugs Sales Value by Application (%), 2023 VS 2030
Figure 53. Southeast Asia Postmenopausal Vaginal Atrophy Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 54. Southeast Asia Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (%), 2023 VS 2030
Figure 55. Southeast Asia Postmenopausal Vaginal Atrophy Drugs Sales Value by Application (%), 2023 VS 2030
Figure 56. India Postmenopausal Vaginal Atrophy Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 57. India Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (%), 2023 VS 2030
Figure 58. India Postmenopausal Vaginal Atrophy Drugs Sales Value by Application (%), 2023 VS 2030
Figure 59. Postmenopausal Vaginal Atrophy Drugs Industrial Chain
Figure 60. Postmenopausal Vaginal Atrophy Drugs Manufacturing Cost Structure
Figure 61. Channels of Distribution (Direct Sales, and Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
